<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02938949</url>
  </required_header>
  <id_info>
    <org_study_id>HM20008008</org_study_id>
    <nct_id>NCT02938949</nct_id>
  </id_info>
  <brief_title>Alirocumab in Patients With Acute Myocardial Infarction</brief_title>
  <official_title>Alirocumab in Patients With Acute Myocardial Infarction: A Randomized Controlled Double-Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IV investigator initiated clinical trial to study the effectiveness of alirocumab, an
      inhibitor of proprotein convertase subtilisin/kexin (PCSK9), versus placebo added to
      high-intensity statin (atorvastatin 80 mg) in lowering low density lipoprotein (LDL)
      cholesterol during non-ST segment elevation myocardial infarction (NSTEMI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research will study the effects of early initiation of alirocumab in addition to high
      intensity statin therapy in patients who have previously been treated with high intensity
      statins with poor response, who present with a type I (spontaneous) acute NSTEMI. Patients
      will be dosed with drug or placebo once during the first day of their hospital admission.
      Blood samples will be collected at baseline, 3 days and 14 days after randomization for
      biomarker testing. Particular attention will be paid to additional LDL lowering effects, as
      well as the effects on PCSK9 levels and inflammatory biomarkers. Safety and tolerability will
      be monitored with complete blood count + differential and complete metabolic panels at each
      study visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">August 16, 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Low-density Lipoprotein (LDL) Cholesterol</measure>
    <time_frame>baseline and 14 days</time_frame>
    <description>Placebo-corrected percentage change in calculated LDL cholesterol from baseline to day 14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Markers (hsCRP)</measure>
    <time_frame>baseline to 3 days</time_frame>
    <description>Placebo-corrected percentage change in inflammatory markers (hsCRP) from baseline to 3 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Markers (hsCRP)</measure>
    <time_frame>baseline to 14 days</time_frame>
    <description>Placebo-corrected Percentage Change in Inflammatory Markers (hsCRP) From Baseline to 14 Days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Alirocumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alirocumab</intervention_name>
    <arm_group_label>Alirocumab</arm_group_label>
    <other_name>Praluent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute type I (spontaneous) NSTEMI defined as chest pain (or equivalent) with an onset
             of symptoms within 12 hours of presentation, a duration of &gt;15 minutes, and elevated
             cardiac troponin I levels, with or without electrocardiographic changes [with the
             exclusion of ST elevation];

          2. On medical therapy with high intensity statin prior to admission (either atorvastatin
             40-80 mg or rosuvastatin 20-40 mg) as documented by hospital or pharmacy records and
             with known LDL cholesterol ≥70 mg/dL within the prior 12 months.

        Exclusion Criteria:

          1. Age &lt;21 years of age

          2. Inability to give informed consent

          3. Previous, current or planned treatment with a PCSK9 inhibitor

          4. Known history of loss of function of PCSK9 (genetic mutation or sequence variation)

          5. Patient with homozygous familial hypercholesterolemia (clinically or by previous
             genotyping)

          6. Recent (&lt;14 days) or active use of immunosuppressive drugs (including but not limited
             to high-dose corticosteroids [&gt;1mg/kg of prednisone equivalent], Tumor Necrosis
             Factor-α blockers, cyclosporine) not including non-steroidal antinflammatory drugs or
             corticosteroids used for IV dye allergy or corticosteroids used as replacement therapy
             for pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to
             randomization (note: topical, intra-articular, nasal, inhaled, and ophthalmic steroid
             therapies are not considered &quot;systemic&quot; and are allowed);

          7. Chronic auto-immune or auto-inflammatory disease (including but not limited to
             rheumatoid arthritis, systemic lupus erythematosus);

          8. History of cancer within the past 5 years, except for adequately treated basal cell
             skin cancer, squamous cell skin cancer, or in situ cervical cancer;

          9. Known chronic hepatitis B or C infection (excluding patients with a positive antibody
             who were successfully treated or who have demonstrated no viral load);

         10. Known human immunodeficiency virus infection.

         11. Use of fibrates other than fenofibrate within 6 weeks of the screening visit.

         12. Uncontrolled hypothyroidism. Note: patients on thyroid replacement therapy can be
             included if the dosage of thyroxin has been stable for at least 12 weeks prior to
             screening.

         13. Known history of a hemorrhagic stroke.

         14. Has been previously treated with at least 1 dose of alirocumab or any other anti-PCSK9
             monoclonal antibody in other clinical studies.

         15. Conditions/situations such as:

               1. Any clinically significant abnormality identified at the time of screening that
                  in the judgment of the investigator or any sub-investigator would preclude safe
                  completion of the study or constrain assessment of endpoints, such as major
                  systemic diseases or patients with short life expectancy.

               2. Patients considered by the investigator or any sub-investigator to be
                  inappropriate for this study for any reason:

             i. Those patients deemed unable to meet specific protocol requirements, such as
             scheduled visits.

             ii. Those patients the investigator deems unable to administer or tolerate long-term
             injections.

             c. Investigator or any sub-investigator, pharmacist, study coordinator, other study
             staff, or relative thereof directly involved in the conduct of the protocol.

             d. Presence of any other conditions (geographic or social), actual or anticipated,
             that the investigator feels would restrict or limit the patient's participation for
             the duration of the study.

         16. Thyroid-stimulating hormone (TSH) &lt; lower limit of normal (LLN) or &gt; upper limit of
             normal (ULN); if TSH is abnormal due to controlled hypothyroidism (patient is on a
             stable dose of thyroid replacement therapy), the patient may be enrolled into the
             study;

         17. Exclusion Criteria Related to the Active Comparator and/or Mandatory Background
             Therapies: All contraindications to the background therapies or warnings/precautions
             of use (when appropriate) as displayed in the respective national product labeling.

         18. Exclusion Criteria Related to the Current Knowledge of Alirocumab

               1. Known hypersensitivity to monoclonal antibody therapeutics

               2. Pregnant or breastfeeding women

         19. Women of childbearing potential who are not protected by highly effective method(s) of
             birth control throughout the entire duration of study treatment and for 10 weeks after
             the last dose of study drug and/or who are unwilling or unable to be tested for
             pregnancy.

         20. Men capable of impregnating women who are not protected by highly effective method(s)
             of birth control and/or who are unwilling to use an effective contraceptive method
             throughout the entire duration of study treatment and for 10 weeks after the last dose
             of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <results_first_submitted>June 28, 2019</results_first_submitted>
  <results_first_submitted_qc>August 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 6, 2019</results_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Low Density Lipoprotein Cholesterol</keyword>
  <keyword>proprotein convertase subtilisin kexin 9, human</keyword>
  <keyword>alirocumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators plan to present the data promptly upon analysis as an abstract to a national meeting and/or a manuscript.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02938949/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alirocumab</title>
          <description>Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
alirocumab</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alirocumab</title>
          <description>Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
alirocumab</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="51" upper_limit="66"/>
                    <measurement group_id="B2" value="56" lower_limit="48" upper_limit="65"/>
                    <measurement group_id="B3" value="59" lower_limit="49" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>body mass index</title>
          <units>kilograms per meters squared</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" lower_limit="24.2" upper_limit="36.8"/>
                    <measurement group_id="B2" value="31.9" lower_limit="28.7" upper_limit="38.8"/>
                    <measurement group_id="B3" value="30.9" lower_limit="25.5" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Low-density Lipoprotein (LDL) Cholesterol</title>
        <description>Placebo-corrected percentage change in calculated LDL cholesterol from baseline to day 14</description>
        <time_frame>baseline and 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alirocumab</title>
            <description>Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
alirocumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Low-density Lipoprotein (LDL) Cholesterol</title>
          <description>Placebo-corrected percentage change in calculated LDL cholesterol from baseline to day 14</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73" lower_limit="-83" upper_limit="-56"/>
                    <measurement group_id="O2" value="2" lower_limit="-12" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Markers (hsCRP)</title>
        <description>Placebo-corrected percentage change in inflammatory markers (hsCRP) from baseline to 3 days</description>
        <time_frame>baseline to 3 days</time_frame>
        <population>Research team was unable to collect samples from 2 Alirocumab participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Alirocumab</title>
            <description>Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
alirocumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Markers (hsCRP)</title>
          <description>Placebo-corrected percentage change in inflammatory markers (hsCRP) from baseline to 3 days</description>
          <population>Research team was unable to collect samples from 2 Alirocumab participants.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="-27" upper_limit="82"/>
                    <measurement group_id="O2" value="55" lower_limit="-25" upper_limit="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt; 0.20</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Markers (hsCRP)</title>
        <description>Placebo-corrected Percentage Change in Inflammatory Markers (hsCRP) From Baseline to 14 Days</description>
        <time_frame>baseline to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alirocumab</title>
            <description>Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
alirocumab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Markers (hsCRP)</title>
          <description>Placebo-corrected Percentage Change in Inflammatory Markers (hsCRP) From Baseline to 14 Days</description>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" lower_limit="-55" upper_limit="71"/>
                    <measurement group_id="O2" value="-33" lower_limit="-48" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.20</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to 14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alirocumab</title>
          <description>Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
alirocumab</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>admission for heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>admission for unstable angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cory Trankle, MD</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-213-2679</phone>
      <email>cory.trankle@vcuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

